anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Frailty is common in older age and is characterised by loss of biological reserves across multiple organ systems. These changes associated with frailty mean older people can be vulnerable to sudden, dramatic changes in health because of relatively small problems. Older people with frailty are at increased risk of adverse outcomes including disability, hospitalisation, and care home admission, with associated reduction in quality of life and increased NHS and social care costs. Personalised Care Planning offers an anticipatory, preventative approach to supporting older adults to live independently for longer, but it has not been robustly evaluated in a population of older adults with frailty.
METHODS: Following an initial feasibility study, this multi-centre, individually randomised controlled trial aims to establish whether personalised care planning for older people improves health-related quality of life. It will recruit 1337 participants from general practices across Yorkshire and Humber and Mid-Mersey in the North of England. Eligible patients will be aged 65 and over with an electronic frailty index score of 0.21 or above, living in their own homes, without severe cognitive impairment and not in receipt of end-of-life care. Following confirmation of eligibility, informed consent and baseline data collection, participants will be individually randomised to the PeRsOnaliSed care Planning for oldER people with frailty (PROSPER) intervention or usual care in a 2.6:1 allocation ratio. Participants will not be blinded to allocation, but data collection and analysis will be blinded. The intervention will be delivered over 12 weeks by a Personal Independence Co-ordinator worker based within a voluntary sector organisation, Age UK. The primary outcomes are health-related quality of life, measured using both the physical and mental components of the Short-Form 12 Item Health Questionnaire at 12 months after randomisation. Secondary outcomes comprise activities of daily living, self-management capabilities and loneliness, admission to care homes, hospitalisations, and health and social care resource use at 12 months post randomisation. Parallel cost-effectiveness and process evaluations will be conducted alongside the trial.
DISCUSSION: The PROSPER study will evaluate the effectiveness and cost-effectiveness of a personalised care planning approach for older people with frailty and inform the process of its implementation.
TRIAL REGISTRATION: ISRCTN16123291 .  Registered on  28 August 2020.
An open, baseline-controlled study in two age groups: adults and elderly. The subjects will be screened within 14 days prior to or at Visit 1 (Day 1). At Visit 1 (Day 1) subjects will be vaccinated after blood sampling for baseline serum antihemagglutinin antibody titration. Subjects will be asked to record local and systemic reactions daily on a diary at home for 72 hours after vaccination. One week later (Visit 2, Day 8) the subjects will return to the study site to hand in the diary and for the assessment of safety and tolerability (reactogenicity and overall inconvenience). Three weeks after vaccination (Visit 3, Day 22) the subjects will return to the study site for blood sampling to assess immunogenicity and for the assessment of safety and tolerability.
Postpartum depression is a common and serious mood disorder influenced by various factors. The global prevalence of postpartum depression has been identified as 17.22%. Depressive symptoms experienced by the mother can affect her daily activities and have a negative impact on infant care. Postpartum depression can also affect mother-infant bonding. A healthy bond between the mother and the baby supports the baby in feeling secure, emotionally satisfied, and adapting to the world. Infant massage has been encouraged in recent years for mothers as it can create positive effects on both depression and maternal attachment. This study provided infant massage training to mothers in the early postpartum period with the aim of preventing postpartum depression and enhancing maternal attachment. The Edinburgh Postnatal Depression Scale (EPDS) was administered to participants on the 14th day postpartum, and those with a score of 12 or below were included in the study. A total of 70 participants were randomly assigned to either the experimental group (35 participants) or the control group (35 participants). The experimental group received a 5-week International Association of Infant Massage (IAIM) Infant Massage Program starting from the 14th day postpartum. The control group did not receive any training or intervention. At the end of the 5 weeks, participants were assessed using the Edinburgh Postnatal Depression Scale and the Maternal Attachment Inventory. The study examined whether there were differences in the mean scores of the scales between the groups.
The project consortium will implement the ARCHES model across two community health centers in Tijuana, Baja California, Mexico. A 2-armed pilot study of ARCHES (adapted) will be conducted with 80 female FP clients (40 intervention, 40 control) ages 16-20 drawn from 2 comparable community health centers randomly assigned to either intervention or control (i.e. standard of care). Baseline data will be collected prior to routine FP service delivery, with a short exit survey conducted immediately following the clients' FP appointment (ARCHES or standard FP counseling will be provided during this visit). Follow-up data will be collected at 3-months post-intervention. Data at each time point will be collected via a 30-minute audio computer-assisted self-interview (ACASI) in Spanish. Data will also be collected to assess qualities of program implementation (i.e., process evaluation) to ensure implementation of the program as intended as well as unforeseen barriers to implementation. Creation of procedures for data collection, review of quality control data, and interpretation of findings will occur in collaboration with the entire mentoring/training committee. In-depth interviews (IDIs) with female adolescent FP clients ages 16-20 with a recent IPV/RC (n= 20), and focus groups (FGs) (n=2; 6-8 participants per group) with FP counselors in 2 comparable urban community health centers to identify perceptions of prevalence and impact of IPV and RC among adolescent clients and barriers to identifying IPV and RC. FGs with FP counselors from the participating community health centers will be conducted (n=2; 6-8 participants per group). FP counselors from these community health centers will be purposely selected to participate based on having provided FP services for at least 10 female adolescent clients in the past 6 months. At intervention sites, FP counselors will deliver the intervention integrated into standard-of-care practice; at control sites FP counselors will deliver solely standard-of-care services. Analyses specific to participants ages 16-20 will provide findings to guide consideration of ARCHES as an effective strategy to improve the reproductive health and reduce GBV among adolescents in this region.
* If changing patients from once-daily TOUJEO (insulin glargine) 300 units/mL to once-daily Insulin glargine, the recommended initial Insulin glargine dose is 80% of the TOUJEO dose that is being discontinued. This dose reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5.3)].
  * If changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with Insulin glargine, a change in the dose of the basal insulin may be required and the amount and timing of the shorter-acting insulins and doses of any oral antidiabetic drugs may need to be adjusted.
  * If changing patients from once-daily NPH insulin to once-daily Insulin glargine, the recommended initial Insulin glargine dose is the same as the dose of NPH that is being discontinued.
  * If changing patients from twice-daily NPH insulin to once-daily Insulin glargine, the recommended initial Insulin glargine dosage is 80% of the total NPH dose that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5.3)].
PROBLEM TO BE SOLVED: To provide a method for facilitating the transfer of nucleic acids into cells, and to provide a novel cationic amphiphile useful for this purpose. SOLUTION: This method for facilitating the transfer for nucleic acids into cells, comprises preparing a mixed lipid dispersion of a cationic lipid with a co-lipid in a suitable carrier solvent. The lipid has a structure which includes a lipophilic group derived from cholesterol, a linker bond selected from the group consisting of (CO)-O and O-(CO), a spacer arm including from about 1 to about 20 carbon atoms in a branched or unbranched linear alkyl chain, and a cationic amino group selected from the group consisting of primary, secondary, tertiary and quaternary amino groups. The method further comprises adding the nucleic acids to the dispersion to form a complex. The cells are then treated with the complex. There is also disclosed a novel cationic amphiphile useful for this purpose.
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to pharmaceutics, specifically to use of dioxidine for treating and/or preventing infectious-inflammatory epithelial injuries and wound healing, to a medicinal agent, pharmaceutical composition, a ready dosage form and a kit for treating and/or preventing infectious-inflammatory epithelial injuries and wound healing. Use of dioxydine involves local application of 0.001–0.4 wt/vol. % aqueous solution of dioxidine with pH from 3 to 7.5. Drug, pharmaceutical composition and the finished dosage form are aqueous 0.001–0.4 wt/vol. % dioxidine solution having pH of 3 to 7.5. Kit contains a bottle with a drug, a pharmaceutical composition or a ready dosage form, a nozzle and instructions for use.EFFECT: group of inventions provides preserving the antimicrobial and anti-inflammatory activity of dioxidine in solutions, high photostability, high resistance to self-oxidation of dioxidine in solutions, high quality of dioxydine solutions and safety thereof due to the absence of microcrystals therein, accelerated healing of wounds and/or burns, recovery of damaged epithelium, reduced complications in treatment, provision of conditions for fast wound epithelisation, wider range of anti-infectious and anti-inflammatory topical agents for treating and/or preventing infectious-inflammatory epithelial injuries.109 cl, 1 dwg, 6 ex, 4 tbl
PURPOSE:To obtain an adsorbent of blood coagulation ninth factor, which is a water-insoluble porous gel having a specific exclusion limit molecular weight, and a sulfur ester group on at least a part of the gel surface. CONSTITUTION:An adsorbent of blood coagulation ninth factor, which is a water-insoluble porous gel (e.g. porous cellulose gel) consisting of hydroxyl group-containing compound having >=50,000, preferably 100,000-2,000,000 exclusion limit molecular weight, and a sulfur ester group on at least a part of the gel surface. By using said adsorbent, a solution containing blood coagulation ninth factor is treated and then the factor is eluted, recovered and readily purified in good yield. The sulfur ester group-containing compound is fixed in water-insoluble porous gel by the bivalent bond and includes sulfated polysaccharide. The blood coagulation ninth factor is useful for treating bleeding of hemophilia B patient.
Cardiogenic shock (CS) is a highly complex clinical condition that requires a management strategy focused on early resolution of the underlying cause and the provision of circulatory support. In cases of refractory CS, mechanical circulatory support (MCS) is employed to replace the failed cardiocirculatory system, thereby preventing the development of multiorgan failure. There are various types of MCS, and patients with CS typically require devices that are either short-term (< 15 days) or intermediate-term (15-30 days). When choosing the device the underlying cause of CS, as well as the presence or absence of concomitant conditions such as failed ventricle, respiratory failure, and the intended purpose of the support should be taken into consideration. Patients with MCS require the comprehensive care indicated in complex critically ill patients with multiorgan dysfunction, with an emphasis on device monitoring and control. Different complications may arise during support management, and its withdrawal must be protocolized.
Surgeons will employ the usual pre-operative counseling in this arm. This will include teaching patients about the anatomy, operative procedures, and potential surgical complications during the pre-operative consent using 2D images.
Group F were administered fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Objective parameters to quantify psoriatic inflammation are needed for interdisciplinary patient care, as well as preclinical experimental models. This study evaluates neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in psoriasis patients and five murine models of psoriasis-like skin disease based on topical imiquimod application and overexpression of IL-17A under different promotors. We performed a single-center prospective observational study in a German population, investigating psoriasis patients prior to, 4 weeks, and 16 weeks post begin of systemic anti-inflammatory therapy. Psoriasis area and severity index (PASI), blood count, and C-reactive protein (CRP) levels were attained at each timepoint. Additionally, five murine models of psoriasis-like skin disease involving five distinct experimental procedures differing in time of disease-onset and severity were investigated regarding PLR and NLR. Of 43 recruited psoriasis patients, 34 patients were followed up to 16 weeks. The cohort was 69.77% male, showing a median age of 32.0 years (range 19.0-67.0; IQR 26). The median PASI decreased from 16.35 (8.0-50.0; 10.20) to 1.6 (0-10.3; 2.56) after 16 weeks of systemic therapy. Spearman's correlation showed statistically significant positive correlation for NLR with PASI (rs = 0.27, p = 0.006), however not for PLR. NLR, but not PLR, was significantly associated with PASI in a multiple linear regression analysis including age, sex, psoriasis arthritis, and smoking. In the murine models of psoriasis-like skin disease, both NLR and PLR were significantly increased in the acute-severe models compared to controls (p < 0.001, p = 0.005, and p = 0.02, respectively), demonstrating gradually less increased values from severe-acute to mild-late-onset psoriatic phenotype. NLR was significantly associated with PASI in psoriatic patients as well as psoriatic phenotype in different murine psoriasis models. Our data warrants investigation of NLR in psoriasis patients and preclinical psoriasis models as an objective biomarker of psoriatic skin inflammation. KEY MESSAGES : NLR, but not PLR, showed a statistically significant positive correlation with Psoriasis Area and Severity Index (PASI) in our human psoriasis cohort. Both NLR and PLR were significantly increased in murine psoriasis models compared to matched controls, with gradually less increased values from severe-acute to mild-late-onset psoriatic phenotype. NLR may represent an easily available, cheap, and objective parameter to monitor psoriatic inflammation in both clinical patient routine, as well as preclinical experimental murine models.
Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue enalapril maleate tablets as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. 

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue enalapril maleate tablets, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to enalapril maleate tablets for hypotension, oliguria, and hyperkalemia [see PRECAUTIONS, Pediatric Use]. 

No teratogenic effects of enalapril were seen in studies of pregnant rats and rabbits. On a body surface area basis, the doses used were 57 times and 12 times, respectively, the maximum recommended human daily dose (MRHDD).
The present invention relates to an externally applied medicine for treating acne, which belongs to a traditional Chinese medicament with traditional Chinese medicines as raw materials. The medicinal ingredients comprise dried alum, realgar, sulfur, litharge, typhonii and white vinegar. The present invention carries out treatment of acne through the synergistic effects of the ingredients based on the principles of dissipating blood stasis, killing germs, detoxicating and beautifying face of Chinese medicines. The externally applied medicine for treating acne has the advantages of simple use, stable curative effect and no recurrence. Mild acne can be cured in about 30 days, moderate acne can be cured in about 45 days, and severe acne can be cured in about 60 days. Through clinical observation of 100 cases of acne patients, the effective rate of the present invention reaches 100%, and the cure rate reaches 97%. The present invention solves the problems of long treatment time, not obvious curative effect, easy recurrence and side effect on human bodies of the existing medicines for treating acne. The present invention is suitable for the treatment of the acne of various types.
[PROBLEMS] To provide a composition comprising a radioactive fluorine-labeled amino acid compound reduced in radiolytic degradation. [MEANS FOR SOLVING PROBLEMS] A composition comprising a radioactive fluorine-labeled amino acid compound and a sugar lactone in an amount effective for the prevention of radiolytic degradation. Preferably, the sugar lactone is selected from the group consisting of ascorbic acid and glucono-σ-lactone. Preferably, the sugar lactone is selected from compounds acceptable as pharmaceutical additives. Preferably, the composition contains the sugar lactone in an amount not less than 0.5 μmol/mL and up to an amount acceptable for a pharmaceutical additive. Preferably, the composition is prepared in such a manner that the radiodensity during use becomes 25 to 125 MBq/mL.
The invention relates to soft capsules for treating apoplexy and a preparation method thereof. The inside of each soft capsule shell is extracts of sanguisuge and raidx astragali, also can be added with extracts of auxiliary Chinese medicaments, such as sanchi, snakegourd fruit, earthworm, ginseng and the like, and is added with relevant auxiliary materials, i.e. a dispersing agent, a suspending agent, an antioxygen, a preservative and the like. The preparation method for the soft capsules comprises the following steps: heating, stirring and melting glycerin, distilled water and expanded gelatin in a gelatin pot; adding the preservative in the gelatin pot; adding the extracts of sanguisuge and raidx astragali, the extracts of other auxiliary Chinese medicaments and liquid melt of beeswax and seed fat; and stirring the mixture into the uniform semi-solid substance. The soft capsules whose effective components are highly dispersed in the substrate are prepared by a pressing method or a dropping preparation method. The soft capsules comprising the extract of sanguisuge and raidx astragali are used for activating blood, eliminating stasis, promoting blood circulation and relieving pain, are suitable to treat meridian qi deficiency and blood stasis type cerebral infarction symptoms in the apoplexy, coronary heart disease, angina, acute myocardial infarction and ischemic cerebral apoplexy, can obviously reduce arteria vertebralis resistance and improve cerebral ischemia and brain circulation, and also can be used for disseminated intravascular coagulation and absorption of intracerebral hematoma of cerebral hemorrhage convalescence and sequelae. The soft capsules of the invention have physicochemical property, stable drug effect and high bioavailability, and can cover bad taste and odor of the medicament.
Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
FIELD: medicine; pharmaceuticals.SUBSTANCE: presented is a dosage form containing esomeprazole or its pharmaceutically acceptable salt for treating gastric and reflux oesophageal diseases. Dosage form comprises a nucleus containing esomeprazole, a layer of endothelial coating formed on the nucleus, and a coating release coating layer formed on the endothelial coating layer. Layer of endothelial coating contains at least one substance selected from hydroxypropyl methyl cellulose, polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, starch and gelatin. Layer of release-controlling coating contains a polymer in which copolymer S of methacrylic acid and copolymer L of methacrylic acid are mixed in weight ratio of 1.5:1 to 3.5:1 as base material of release-controlling coating, where methacrylic acid copolymer S is an anionic copolymer containing methacrylic acid and methyl methacrylate in ratio of 1:2, and methacrylic acid copolymer L is an anionic copolymer containing methacrylic acid and methyl methacrylate in ratio of 1:1. Weight of copolymer S of methacrylic acid and copolymer L of methacrylic acid as base materials of release-controlling coating ranges from 15 to 40 % relative to weight of the tablet with endothelial coating. Dosage form when eliciting release after 2 hours elutes 5 % or less of esomeprazole or its pharmaceutically acceptable salt, and after 6 hours eluates at least 90 % of esomeprazole or its pharmaceutically acceptable salt. Described also is a method for preparing a dosage form of esomeprazole.EFFECT: dosage form according to the invention is characterized by improved characteristics of pH-dependent release of the preparation, starts releasing esomeprazole or its pharmaceutically acceptable salt after a given delay time for oral administration, continues release for a given time and ends the release through a predetermined time, thereby providing excellent patient comfort and excellent therapeutic effects compared to other standard forms.8 cl, 2 dwg, 10 tbl, 4 ex